Avid Bioservices Inc (CDMO)

[biopharm]

In an exploratory analysis of OS for patients who received subsequent immune checkpoint inhibitors (ICI), the mOS was not reached (95% CI, 15.2-NA) in B+D (n=46) and 12.6mos. (95% CI, 10.4-17.8) in D (n=47) (HR=.46; P=.006).

Looks like we have CTOs / patents filed to keep other Biomarkers classified / Roche another CTO that can't be made public till 2021 and Roche ties into Halozyme ... an Avid Bioservices client

One should always wonder why Avid was chosen for the start of HALO contracts and as I always said.... just a new twist into how Big Pharma can pay to delay new, paradigm shifting medical treatment that rocks the boat

Historic MOS survival rates and not a peep from Avid or Oncologie or UTSWM or Lonza